1. RO TA RUS V CCI E
VI A N
T E T SAVE YOUR K
IM O IDS
DR.SMRUTIRANJAN PATANAIK

2. RO TA RUS
VI
 A VIRUS OF THE FAMILY
REOVIRIDAE
 WHEEL SHAPED APPEARANCE –
ROTA
 MAJOR CAUSE OF DIARRHEA AND
GASTROENTERITIS UNDER THE
AGE OF FIVE
 MORTALITY 6 LAKHS ACROSS THE
GLOBE (29 TO 45 % OF ALL
DIARRHEAL DEATHS)
 OVER 2 MILLION HOSPITALIZED
EACH YEAR

3. STRUCTURE
CLASSIFICATION
BASIS :- IMMUNOLOGICAL REACTIVITIES OF VARIOUS
COMPONENTS OF PARTICLES & FROM
GENOMIC COMPOSITION INTO GROUPS A-G:-
GROUP A HAVING SEROTYPES & GENOTYPES

4. REPLI TI N
CA O
SITE- CYTOPLASM OF ENTEROCYTES
REMOVAL OF OUTER CAPSID
mRNA SYNTHESIS
mRNA (CYTOPLASM)
TRANSLATION
VIRAL PROTEINS
VIROPLASM
REPLICATION
ds RNA
DOUBLE SHELLED PARTICLES FORMED
VIRUS RELEASED

5. ROUTE OF TRANSMISSION-FAECO ORAL
ROUTE (1012 VIRIONS PER GM. OF EXCRETA
IN ACUTE INFECTION)
INFECTIVE DOSE-LOW (100-1000 VIRAL
PARTICLES)
INCUBATION PERIOD-2 TO 3 DAYS
IMMUNITY:-
IgA ANTIBODIES
CTL

6. NEED FO R AV CCI E
A N
 NATURALLY ACQUIRED IMMUNITY AFTER THE DISEASE.
 TRANSMISSION RATES UNAFFECTED BY IMPROVING
SANITATION.
 UNAVAILABILITY OF LIFE SAVING I.V. TREATMENT TO
ALL PATIENTS.
 COST EFFECTIVE METHODS.
HISTORYOF VACCINE DEVELOPMENT
• 1993-94—LIVE ATTENUATED ROTAVIRUS VACCINE
FROM RHESUS MONKEY.
• 1996-COCKTAIL VACCINE (RRV-TV).
• 1998-ROTASHIELD

7. PRESEN V CCI ES A ALA LE
T A N VI B

8. CHALLEN GES FO R V CCI E
A N
I TRO DUCTI N& FUTURE PRO SPECTS
N O
UNCERTAIN DEMAND, INSUFFICIENT SUPPLY
AND HIGH PRICES OF THE VACCINE.
LACK OF INFORMATION ON BURDEN OF
DISEASE IN SOME COUNTRIES.
NEW EMERGING MUTANT & RECOMBINANT
STRAINS OF VIRUS.

9. I AN
N UTSHELL
THE 2 VACCINES ROTATEQ AND ROTARIX
LAUNCHED IN THE YEAR 2006 HELP IN
PREVENTION OF ROTAVIRUS INFECTION AT THE
ENTEROCYTE LEVEL HAVING A PROMISING
EFFICACY OF AROUND 95 TO 100%.